Dinaciclib induces immunogenic cell death and enhances anti-PD1–mediated tumor suppression

Blockade of the checkpoint inhibitor programmed death 1 (PD1) has demonstrated remarkable success in the clinic for the treatment of cancer; however, a majority of tumors are resistant to anti-PD1 monotherapy. Numerous ongoing clinical combination therapy studies will likely reveal additional therap...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Invest
Päätekijät: Hossain, Dewan Md Sakib, Javaid, Sarah, Cai, Mingmei, Zhang, Chunsheng, Sawant, Anandi, Hinton, Marlene, Sathe, Manjiri, Grein, Jeff, Blumenschein, Wendy, Pinheiro, Elaine M., Chackerian, Alissa
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Clinical Investigation 2018
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5785250/
https://ncbi.nlm.nih.gov/pubmed/29337311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI94586
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia